<DOC>
	<DOCNO>NCT00901771</DOCNO>
	<brief_summary>The primary objective propose investigation evaluate efficacy Provent device sample OSA patient either refuse non-adherent PAP treatment . Both initial efficacy ( evaluate approximately one week Provent ) efficacy approximately 5 week patient demonstrate initial efficacy assess . A secondary objective ass adherence Provent treatment 5-week evaluation period .</brief_summary>
	<brief_title>Study Provent Treatment Obstructive Sleep Apnea Patients Who Are Non-compliant With CPAP</brief_title>
	<detailed_description />
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>Current sign symptom consistent diagnosis OSA opinion study physician Rejection PAP treatment minimally adherent PAP treatment Use Provent device specify amount time night three consecutive night trial period AHI &gt; 15 , AHI &gt; 10 evidence CMSrecognized symptom co morbidity , screening/baseline PSG Investigator believe subject benefit OSA treatment Subject understand willing able comply study requirement Use device interferes nasal oral breathing Persistent blockage one nostrils prevents airflow one nostrils Any chronic sore lesion inside outside nose Chronic use nasal decongestant nasal steroid History allergic reaction acrylicbased adhesive ( find BANDAIDSÂ® ) Current acute upper respiratory ( include nasal , sinus , middle ear ) inflammation infection perforation tympanic membrane ( may reconsider participation acute episode resolve ) History frequent and/or poorly treat severe nasal allergy sinusitis may interfere ability use Provent Severe respiratory disorder ( include respiratory muscle weakness , bullous lung disease , bypass upper airway , pneumothorax , pneumomediastinum , etc. ) . Pathologically low blood pressure . Narcolepsy , idiopathic hypersomnolence , chronic insomnia , restless legs syndrome , REM sleep behavior disorder diagnose suspected sleep disorder OSA could affect likelihood apneas/hypopneas PSG . Periodic limb movement arousal index ( PLMAI ) &gt; 10 screening/baseline PSG . Current use diurnal nocturnal supplemental oxygen Currently work night rotate shift Consumption &gt; 10 caffeinated beverage per day ( approximately 1000 mg per day ) History severe cardiovascular disease , include New York Heart Association Class III IV heart failure , coronary artery disease angina myocardial infarction past 6 month , stroke past 6 month History cardiac rhythm disturbance ( define 5beat run sustain ventricular tachycardia bradycardia &lt; 30 beat per min 10second run previously undiagnosed untreated atrial fibrillation Mobitz II thirddegree heart block ) Current psychiatric disorder psychotic feature . Pregnant try become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Sleep</keyword>
	<keyword>Sleep Apnea , Obstructive</keyword>
	<keyword>OSA</keyword>
	<keyword>OSAH</keyword>
</DOC>